NCT02054754 is a Phase 1 clinical trial of Dexanabinol Dose Level 1 in Safety, sponsored by e-Therapeutics PLC.

Who is sponsoring NCT02054754?

NCT02054754 is sponsored by e-Therapeutics PLC.

What drugs are being tested in NCT02054754?

Interventions in NCT02054754: Dexanabinol Dose Level 1, Dexanabinol Dose Level 2, Dexanabinol Dose Level 3, Dexanabinol Dose Level 4, Dexanabinol Dose Level 5, Placebo.

What condition does NCT02054754 study?

NCT02054754 studies Safety, Tolerability, Pharmacokinetics, Cancer.

Is NCT02054754 still recruiting?

NCT02054754 is currently completed. Last updated 17 May 2016.

Are results published for NCT02054754?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2016-05-17 · How we verify

NCT02054754

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects

Completed Phase 1 Results posted Last updated 17 May 2016

What this trial tests

Phase 1 trial testing Dexanabinol Dose Level 1 in Safety in 40 participants. Completed in 1 September 2014.

Timeline

1 January 2014

Primary endpoint
1 September 2014

1 September 2014

Quick facts

Lead sponsor	e-Therapeutics PLC
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	40
Start date	1 January 2014
Primary completion	1 September 2014
Estimated completion	1 September 2014
Sites	1 location across United Kingdom

Drugs / interventions tested

Dexanabinol Dose Level 1 — full drug profile →
Dexanabinol Dose Level 2 — full drug profile →
Dexanabinol Dose Level 3 — full drug profile →
Dexanabinol Dose Level 4 — full drug profile →
Dexanabinol Dose Level 5 — full drug profile →
Placebo

Conditions studied

Safety — all drugs for Safety →
Tolerability — all drugs for Tolerability →
Pharmacokinetics — all drugs for Pharmacokinetics →
Cancer — all drugs for Cancer →

Sponsor

e-Therapeutics PLC — full company profile →

Who can join

Adults 18 to 45, male only, with Safety or Tolerability. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety and Tolerability Based on the Number of Participants With Adverse Events and Comparison of Baseline and Post Dose Parameters
Time frame: Participants will be followed until follow up visit, 6-11 days after dosing
Safety and tolerability based on the number of participants with adverse events. Assessment and comparison to baseline of the following: * Physical exam * Safety bloods and urinalysis * 12-lead ECG * Vital signs

Sponsor's own description

The purpose of this study is to test the safety and observe the pharmacokinetics (distribution and elimination of the drug) of the compound dexanabinol (ETS2101) in healthy male subjects following a single oral dose.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

The current state and future perspectives of cannabinoids in cancer biology.
Śledziński P, Zeyland J, Słomski R, Nowak A. · · 2018 · cited 100× · PMID 29473338 · DOI 10.1002/cam4.1312
Cannabinoids in the landscape of cancer.
Mangal N, Erridge S, Habib N, Sadanandam A, et al · · 2021 · cited 72× · PMID 34259916 · DOI 10.1007/s00432-021-03710-7
Rescuing mitochondria in traumatic brain injury and intracerebral hemorrhages - A potential therapeutic approach.
Ahluwalia M, Kumar M, Ahluwalia P, Rahimi S, et al · · 2021 · cited 35× · PMID 34560175 · DOI 10.1016/j.neuint.2021.105192
Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype.
Almeida CF, Teixeira N, Correia-da-Silva G, Amaral C. · · 2021 · cited 26× · PMID 35011388 · DOI 10.3390/molecules27010156

Verify or expand the search:

Other recruiting trials for Safety

Currently open trials in the same condition.

NCT06818994 — Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced · Phase 1 · recruiting
NCT07286656 — A Study of GensSci098 in Subjects With Graves' Disease · Phase 1 · recruiting
NCT06760208 — A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market · recruiting
NCT07157215 — An International Survey on the Use of NIV Outside the ICU · recruiting
NCT06976229 — Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02054754 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by e-Therapeutics PLC
Last refreshed: 17 May 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02054754.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing